Journal
EPIGENOMICS
Volume 9, Issue 4, Pages 505-525Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/epi-2016-0096
Keywords
biomarker; chromatin; CREM; DNMT; epigenetics; inflammation; methylation; SLE; transcription factor; treatment
Categories
Funding
- intramural MeD-Drive program, TU Dresden and the Fitz-Thyssen Foundation
- National Institutes of Health
Ask authors/readers for more resources
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease facilitated by aberrant immune responses directed against cells and tissues, resulting in inflammation and organ damage. In the majority of patients, genetic predisposition is accompanied by additional factors conferring disease expression. While the exact molecular mechanisms remain elusive, epigenetic alterations in immune cells have been demonstrated to play a key role in disease pathogenesis through the dysregulation of gene expression. Since epigenetic marks are dynamic, allowing cells and tissues to differentiate and adjust, they can be influenced by environmental factors and also be targeted in therapeutic interventions. Here, we summarize reports on DNA methylation patterns in SLE, underlying molecular defects and their effect on immune cell function. We discuss the potential of DNA methylation as biomarker or therapeutic target in SLE.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available